---
title: "Ensysce Biosciences surges 51% in regular trading after acquiring CRPS drug candidate CY200"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295128140.md"
description: "Ensysce Biosciences surged 51% after completing Cy Biopharma acquisition for CRPS candidate CY200."
datetime: "2026-08-06T16:28:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295128140.md)
  - [en](https://longbridge.com/en/news/295128140.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295128140.md)
---

# Ensysce Biosciences surges 51% in regular trading after acquiring CRPS drug candidate CY200

Ensysce Biosciences(ENSC.US) 盘中急涨，当日涨幅达 51.44%，现报 0.5482 美元。

消息面上，公司近日完成对 Cy Biopharma 的收购，获得处于临床阶段的复杂区域疼痛综合征候选药物 CY200。该交易包含 1710 万美元现金及一项目标募资 2150 万美元的定向增发，另有 3860 万美元后续资金与临床里程碑挂钩。资金将支持该药物至 2028 年的二期开发和注册准备。

此外，公司发布的投资者演示文件重点介绍了其胰蛋白酶控制阿片类药物平台 TAAP 和 MPAR，相关产品已于 2024 年 1 月获 FDA 突破性疗法认定。开发计划包括 2026 年启动 PF614-MPAR 的 1b/3 期临床试验，以及 2028 年提交新药申请。

### Related Stocks

- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)

## Related News & Research

- [Ensysce Biosciences Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295841617.md)
- [Ensysce Biosciences posts investor presentation spotlighting trypsin-controlled opioid platforms, pain pipeline](https://longbridge.com/en/news/295107304.md)
- [Ensysce Biosciences completes Cy Biopharma acquisition](https://longbridge.com/en/news/295106106.md)
- [Ensysce enrolls first patient in final phase of PF614-MPAR-102 overdose-protection trial](https://longbridge.com/en/news/290962389.md)
- [Ensysce Biosciences GAAP EPS of -$0.52 beats by $0.21](https://longbridge.com/en/news/286613093.md)